Practical Radiation Oncology Program 2023
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a coding update and a scientific overview.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation therapists, radiation dosimetrists, medical oncologists, surgeons, physicists, nurses, pathologists, and urologists.
Upon completion of this activity, participants should be able to do the following:
- Discuss various techniques for breast cancer patient set-up and motion management.
- Discuss hypofractionation and ultra-hypofractionation techniques.
- Identify the different treatment strategies for sarcoma based on clinical presentation.
- Implement different treatment techniques for sarcoma based on clinical scenario.
- Discuss treatment of larynx cancers for different stages of disease.
- Manage care of long-term survivors of larynx cancer.
- Contour planning volumes to the current standard of care in lung cancer management.
- Select appropriate dose/fractionation schedule for common palliative scenarios in lung cancer management.
- Know appropriate fractionation schemes for retreatment in the central nervous system, head and neck, and prostate.
- Understand the risk/benefit ration of retreatment in the central nervous system, head and neck, and prostate and be able to communicate this to patients.
- Assess their existing brachytherapy capabilities for treatment of gynecologic cancers and evaluate ways to enhance access and capabilities in a community setting.
- Select patients for appropriate treatment of recurrent or inoperable endometrial cancer and navigate anatomic or technical challenges to provide quality radiation care.
- Incorporate information to improve the management of primary and metastatic brain tumors.
- Return to their teams with techniques to improve their radiosurgery programs in the treatment of primary brain tumors.
- Comfortably differentiate patients with oligometastatic disease that may benefit from radiation therapy in the context of recent supportive studies.
- Assess their available resources and apply safe, effective radiation when indicated with greater comfort of dose, technique, timing, and prognostication principles specific to metastasis-directed radiation.
- Discuss the multidisciplinary management of esophagogastric, borderline resectable pancreatic and rectal cancer.
- Optimize radiation techniques and plans for esophagogastric, borderline resectable pancreatic and rectal cancer.
- Assess updated dose limits to critical structures to minimize long term morbidity.
- Determine what data and testing is available to tailor the use of androgen deprivation therapy in intermediate risk and post prostatectomy patients.
- Explain the combinations and sequencing of systemic therapies for high risk, node positive, and metastatic prostate cancer patients.
The program is comprised of ten sessions:
- Updates in Breast Cancer: Hypofractionation, Treatment Techniques, and Systemic Therapy
- Hypofractionation for Breast Cancer—Nicolas Prionas, MD, PhD
- Breast Radiation Techniques and Motion Management—Jolinta Lin, MD
- Advances in Systemic Therapy for Breast Cancer—Cathie Chung, MD
- The Who, What and How of Sarcoma
- Overview of Sarcoma—Manpreet Bedi, MD, MS
- Multidisciplinary Management of Sarcoma—Andrew Bishop, MD
- Unresectable and Metastatic Disease—Anusha Kalbasi, MD
- Radiation Technique and Case Presentation—Shauna Campbell, MD, DO
- Treatment and Management of Larynx Cancer
- Early Stage Larynx Cancer—David Sher, MD, MPH
- Locally Advanced Larynx Cancer—Zain Husain, MD
- Treatment Strategies in Post Operative and Recurrent Larynx Cancer—Gary Walker, MD, MS, MPH
- Updates in Lung Cancer Management
- Current Management of Stage III Non Small Cell Lung Cancer—Saumil Gandhi, MD, PhD
- Non Definitive Lung Options: Palliation and XRT Alone—Uzoma Iheagwara, MD, PhD
- Small Cell Lung Cancer Treatment Volumes—Sara Zakem, MD, BS
- Reirradiation for Prostate, CNS and Head and Neck Cancers
- Reirradiation for Local Recurrence of Prostatic Carcinoma—Abhishek Solanki, MD, MS
- Reirradiation in Primary and Metastatic CNS Malignancy—Susan McGovern, MD, PhD
- Pro Retreatment: Head and Neck—James Caudell, MD, PhD
- Inoperable/Recurrent Endometrial Cancer and Building a Brachytherapy Practice in a Community Setting
- Inoperable Endometrial Cancer—J. Spencer Thompson, MD
- Recurrent Endometrial Cancer—Emma Fields, MD
- Implementing a Successful Brachytherapy Program in the Community—Malolan Rajagopalan, MD, MBA
- Management of Primary Brain Tumors in the Molecular Era and Building and Refining a Radiosurgery Program
- Management of Gliomas in the Molecular Era—Sara Hardy, MD, MS
- Management of Large and Multiple Brain Metastases—Raju Raval, MD, DPhil
- Starting and Refining a Radiosurgery Program—Roshan Prabhu, MD, MS
- Oligometastatic Disease: Practical Aspects of Metastasis-Directed Therapy in a Community Practice
- Data and Dose Selection: To Ablate or Not to Ablate?—Beant Gill, MD
- Prognostication, Timing, and Patient Selection—David Palma, MD, PhD
- Setting Up for Success—Melissa O'Neil, MRT(T)
- Maximizing Patient Outcomes and Minimizing Morbidity in Gastrointestinal Cancer
- Optimizing Multimodality Management of Gastroesophageal Junction Cancer—Edward Kim, MD
- TNT, W&W, and Beyond: Applying the Explosion of Data to Rectal Cancer Practice—Krishan Jethwa, MD
- Advances in Radiation for Pancreatic Cancer—Erqi Pollom, MD, MS
- Personalization of Systemic Therapy for Localized to Metastatic Prostate Cancer
- Personalizing ADT Use in the Definitive Treatment of Intermediate Risk Prostate Cancer—Angela Jia, MD, PhD
- Duration and Combination of Systemic Therapies for Patients with High Risk, Node Positive, and Oligometastatic Prostate Cancer—Anne Rajkumar, MD
- Overview of Systemic Therapies in Metastatic Prostate Cancer—Rana Mckay, MD
This activity is available from December 15, 2023, through 11:59 p.m. Eastern time on December 14, 2024.
This activity was originally recorded at the 2023 ASTRO Annual Meeting.
A list of all meeting faculty and Individual presenter disclosures are in the 2023 ASTRO Annual Meeting Faculty and Presenters' Disclosure or Relationships. All relevant financial relationships have been mitigated.
The ASTRO Education Committee and the 2023 ASTRO Annual Meeting Education and Steering Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 12.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 12.50 Certificate of AttendanceThis activity was designated for 12.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $699
- Member: $599
- Postdoctoral Fellow Member:$
- Member-in-Training: $299
- Student/Grad Student/PGY-1 Member: $299
No refunds, extensions, or substitutions will be made for those registrants. Including those who for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 2 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.”
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.